GlassScriptPhysician profile
Todd Alan Pitts
NPI 1962045575
$10,042.14
in general payments reported to CMS, 2019-2025
55 companies · $1,551 in 2025
The $1,551 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $123 · 2022: $2,503 · 2023: $2,603 · 2024: $3,263 · 2025: $1,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,724 · Travel and Lodging: $373 · Education: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,724.49 |
| Travel and Lodging | $372.84 |
| Education | $319.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,958.93 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,220.48 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,007.84 | 2021-2025 | |
| Medtronic, INC. | $805.25 | 2022-2025 | Synchromedii, Intellis Adaptivestim, Inceptiv |
| Dexcom, INC. | $628.57 | 2022-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $395.25 | 2023-2025 | |
| Medical Device Business Services, INC. | $362.85 | 2025 | Stratafix |
| Amgen INC. | $322.23 | 2021-2024 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $273.58 | 2022 | |
| Phathom Pharmaceuticals, INC. | $244.07 | 2024 | Voquezna |
| Exact Sciences Corporation | $235.40 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $205.14 | 2022-2024 | Trintellix |
| Antares Pharma, INC. | $194.06 | 2022-2024 | Xyosted, Nocdurna, Tlando |
| Neos Therapeutics, LP | $191.45 | 2021-2024 | Adzenys Xr-Odt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.31 | 2022-2024 | Xifaxan |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.17 | 2022-2024 | Jardiance |
| Ironwood Pharmaceuticals, INC | $139.51 | 2022-2024 | Linzess |
| Intra-Sana Laboratories | $114.72 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Nalu Medical, INC. | $108.42 | 2025 | Nalu Neurostimulation System |
| Otsuka America Pharmaceutical, INC. | $106.08 | 2022-2024 | Rexulti |
| Ardelyx, INC. | $88.20 | 2024 | Ibsrela |
| Cvrx, INC. | $84.78 | 2022 | |
| Shield Therapeutics INC | $77.22 | 2022-2024 | Accrufer |
| Corium, LLC | $72.00 | 2023 | Azstarys |
| Halozyme INC | $70.47 | 2023 | |
| Hologic Sales and Service, LLC | $69.13 | 2021-2024 | Aptima |
| Xeris Pharmaceuticals, INC. | $61.81 | 2022-2023 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $58.58 | 2022-2023 | |
| Almatica Pharma LLC | $56.69 | 2023-2024 | Loreev Xr, Gralise |
| Idorsia Pharmaceuticals US INC | $47.53 | 2022-2023 | Quviviq |
| Glaxosmithkline, LLC. | $45.19 | 2022-2024 | Trelegy Ellipta |
| Neurocrine Biosciences, INC. | $37.95 | 2022 | |
| Esperion Therapeutics, INC. | $32.95 | 2022 | |
| Boston Scientific Corporation | $27.16 | 2024 | |
| Tolmar, INC. | $26.81 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $21.33 | 2023 | Strensiq |
| Becton, Dickinson and Company | $21.32 | 2025 | Avitene Ultrafoam |
| Inari Medical, INC. | $21.13 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Paratek Pharmaceuticals, INC. | $19.88 | 2022 | |
| Noven Therapeutics, LLC | $19.78 | 2024 | Xelstrym |
| Corcept Therapeutics | $18.65 | 2023 | Korlym |
| Astrazeneca Pharmaceuticals LP | $18.08 | 2024 | Airsupra |
| Tandem Diabetes Care, INC. | $17.76 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $16.74 | 2024 | |
| Astellas Pharma US INC | $16.48 | 2024 | Veozah |
| Upsher-Smith Laboratories LLC | $14.85 | 2023 | |
| Merck Sharp & Dohme LLC | $14.77 | 2022 | |
| Currax Pharmaceuticals LLC | $14.56 | 2025 | Contrave, Onzetra Xsail |
| Vivus LLC | $13.68 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.56 | 2024 | Caplyta |
| Collegium Pharmaceutical, INC. | $13.18 | 2022 | |
| Axsome Therapeutics, INC. | $13.10 | 2023 | Auvelity |
| Jazz Pharmaceuticals INC. | $12.88 | 2022 | |
| Nabriva Therapeutics, Plc | $12.83 | 2022 | |
| Tris Pharma INC | $12.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Pitts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.